Valuation: Bonesupport Holding AB

Market Cap 15.81B 1.64B 1.43B 1.32B 1.22B 2.32B 156B 2.36B 6.2B 76.69B 6.14B 6.01B 266B P/E 2026 *
52x
P/E 2027 * 31.9x
Enterprise Value 15.19B 1.57B 1.38B 1.27B 1.17B 2.23B 150B 2.27B 5.96B 73.71B 5.9B 5.78B 255B EV / Sales 2026 *
10.1x
EV / Sales 2027 * 7.49x
Free-Float
85.24%
Yield 2026 *
0.6%
Yield 2027 * 0.9%

Last Transcript: Bonesupport Holding AB

1 day-6.10%
1 month-14.37%
3 months-14.26%
6 months+5.94%
Current year+8.11%
1 month 21.4
Extreme 21.4
22.79
Current year 19
Extreme 19
28.57
1 year 18.57
Extreme 18.57
35
3 years 15.74
Extreme 15.74
35
5 years 3.83
Extreme 3.83
35
10 years 3.83
Extreme 3.83
35
Manager TitleAgeSince
Chief Executive Officer 49 2025-08-31
Director of Finance/CFO 63 2018-10-31
Chief Operating Officer 51 2021-11-30
Director TitleAgeSince
Director/Board Member 68 2009-12-31
Chairman 70 2016-12-14
Chairman 71 2019-05-13
Change 5-day change 1-year change 3-year change Capi.($)
-6.10%-.--% - - 1.64B
-0.85%+1.99%+18.39%-5.78% 67.96B
-5.16%-8.63%+37.37%+202.27% 54.4B
-2.10%+4.37%-49.58%-53.96% 41.74B
+5.28%+39.50%+39.50%+39.50% 40.63B
-10.70%-16.11%+100.18%-44.25% 30.38B
-0.48%-5.06%+46.24%-29.71% 29.37B
-2.11%+0.19%+64.69%+87.18% 23.68B
+3.88%+5.10%+9.06%+196.53% 19.15B
-3.42%+12.17%+88.48%+402.36% 17.68B
Average -2.17%+1.28%+39.37%+88.24% 36.11B
Weighted average by Cap. -1.82%+0.38%+32.28%+63.66%

Financials

2026 *2027 *
Net sales 1.5B 155M 136M 125M 116M 220M 14.79B 223M 587M 7.26B 582M 569M 25.16B 1.98B 205M 180M 166M 153M 291M 19.61B 296M 778M 9.63B 771M 754M 33.35B
Net income 309M 31.99M 27.99M 25.81M 23.88M 45.33M 3.05B 46.09M 121M 1.5B 120M 118M 5.19B 508M 52.58M 45.99M 42.41M 39.24M 74.48M 5.02B 75.73M 199M 2.46B 197M 193M 8.54B
Net Debt -613M -63.49M -55.54M -51.22M -47.39M -89.95M -6.06B -91.45M -240M -2.98B -238M -233M -10.31B -948M -98.13M -85.84M -79.16M -73.24M -139M -9.37B -141M -372M -4.6B -368M -360M -15.93B
Logo Bonesupport Holding AB
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Employees
160
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
240.00SEK
Average target price
371.83SEK
Spread / Average Target
+54.93%

Quarterly revenue - Rate of surprise